Supplemental Figure 3 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients | Synapse
September 16, 2024
Supplemental Figure 3 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients
Key Points
Key points are not available for this paper at this time.
Abstract
Supplemental Figure 3: Baseline AF% of patients with complete clearance and patients with incomplete clearance at C2.